ERBB2 and gastric cancer: Probably owing to this dynamic feature, trastuzumab deruxtecan represents a good strategy for heterogeneous tumors, such as gastric cancer in which HER2 overexpression may vary from cell to cell or even across different metastatic locations within the same patient [19,44].